Related Experiment Video
Updated: Jul 4, 2025
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors
Megan Rutherford1, Margaret Wheless2, Katharine Thomas3
1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract:
Pulmonary neuroendocrine tumors represent a spectrum of disease ranging from typical carcinoid tumors to small cell lung cancers. The incidence of low-grade pulmonary NETs has been increasing, leading to improved awareness and the need for more treatment options for this rare cancer. Somatostatin analogs continue to be the backbone of therapy and may be followed or accompanied by targeted therapy, chemotherapy, and immune therapy. The recent addition of peptide receptor radionuclide therapy (PRRT) to the treatment armamentarium of NETs has led to the development of targeted alpha therapy to overcome PRRT resistance and minimize off-target adverse effects. Herein, we aim to highlight current treatment options for patients with advanced low grade pulmonary NETs along with emerging therapies, sequencing of therapies, upcoming clinical trials, and the importance of a multidisciplinary team to improve patient outcomes.
Insights
Advanced low-grade pulmonary neuroendocrine tumors (NETs) require diverse treatments. Emerging therapies like targeted alpha therapy offer new options beyond somatostatin analogs, chemotherapy, and PRRT.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Pulmonary neuroendocrine tumors (NETs) encompass a range from typical carcinoids to small cell lung cancer.
- Increasing incidence of low-grade pulmonary NETs necessitates enhanced treatment strategies.
Purpose of the Study:
- To review current and emerging treatments for advanced low-grade pulmonary NETs.
- To discuss therapeutic sequencing, clinical trials, and multidisciplinary care.
Main Methods:
- Literature review of current treatment options for pulmonary NETs.
- Exploration of emerging therapies, including peptide receptor radionuclide therapy (PRRT) and targeted alpha therapy.
- Emphasis on the role of a multidisciplinary team.
Main Results:
- Somatostatin analogs remain a cornerstone of therapy.
- Targeted therapies, chemotherapy, and immunotherapy are also utilized.
- Peptide receptor radionuclide therapy (PRRT) and targeted alpha therapy represent advancements.
Conclusions:
- A comprehensive, multidisciplinary approach is crucial for managing advanced low-grade pulmonary NETs.
- Emerging therapies offer promising alternatives and adjuncts to existing treatments.
- Further research and clinical trials are essential to optimize patient outcomes.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
